Skip to main content

Table 2 Vitamin D metabolite level at baseline and day 3 after enrollment

From: Trying to identify who may benefit most from future vitamin D intervention trials: a post hoc analysis from the VITDAL-ICU study excluding the early deaths

Vitamin D metabolite Survivors at 28 days
Mean (CI 95%)
Non-survivors at 28 days
Mean (CI 95%)
p value
Vitamin D supplementation group, day 0
 25-Hydroxyvitamin D, ng/ml 12.9 (12.2–13.6) 13.0 (11.3–14.7) 0.869
 1,25-Dihydroxyvitamin D, pg/ml 44.3 (37.1–51.4) 38.3 (21.9–54.7) 0.527
Placebo group, day 0
 25-Hydroxyvitamin D, ng/ml 13.6 (12.9–14.4) 12.9 (11.6–14.4) 0.382
 1,25-Dihydroxyvitamin D, pg/ml 42.9 (36.3–49.4) 34.6 (25.9–43.3) 0.133
Vitamin D supplementation group, day 3
 25-Hydroxyvitamin D, ng/ml 34.4 (31.7–37.2) 25.4 (20.2–30.6) 0.010
 1,25-Dihydroxyvitamin D, pg/ml 107.6 (92.7–122.6) 70.3 (36.0–104.7) 0.056
Placebo group, day 3
 25-Hydroxyvitamin D, ng/ml 13.9 (13.2–14.7) 13.9 (12.1–15.7) 0.948
 1,25-Dihydroxyvitamin D, pg/ml 50.7 (42.2–59.2) 37.4 (26.5–48.4) 0.059